FindTrial
Sign In

Anti-infectious therapy guided by metagenomics next generation sequencing technology in sepsis: a single center randomized controlled study

Anti-infectious therapy guided by metagenomics next generation sequencing technology in sepsis: a single center randomized controlled study

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2000028897
Enrollment
Unknown
Registered
2020-01-06
Start date
2020-02-01
Completion date
Unknown
Last updated
2020-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

sepsis

Interventions

Experimental group:mNGS results guided anti-infection therapy
Control group:Traditional anti-infection treatment

Sponsors

The Third Affiliated Hospital, Sun Yat-Sen University
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Aged >= 18 years; 2. Consistent with the diagnosis of sepsis or septic shock; 3. Agree to participate in this clinical study and sign a written informed consent.

Exclusion criteria

Exclusion criteria: 1. Patients who suffer from serious basic diseases, such as respiratory failure, heart failure, liver failure, advanced malignancy etc, which may cause death of the patient in the near future; 2. Patient will probably be discharged within the first 72 h following inclusion or palliative treatment intent; 3. Pregnant or lactating women; 4. Patients who have history of mental illness.

Design outcomes

Primary

MeasureTime frame
90d mortality;—

Countries

China

Contacts

Public ContactZheng Changlong

The Third Affiliated Hospital, Sun Yat-Sen University

zhengchanglong@163.com+86 13316266823

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026